The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Remnant cholesterol and intensive blood pressure control in older patients with hypertension: a post hoc analysis of the STEP randomized trial
Abstract
Aims: Emerging evidence shows a close relationship between remnant cholesterol (RC) and hypertension. However, it is unknown whether RC is associated with the effects of intensive systolic blood pressure (SBP) lowering on cardiovascular outcomes. Methods and results: We performed a post hoc analysis of the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial. Participants were randomly allocated to intensive (110 to <130 mmHg) or standard (130 to <150 mmHg) treatment groups. The effects of intensive SBP lowering on the primary composite outcome (stroke, acute coronary syndrome, acute decompensated heart failure, coronary revascularization, atrial fibrillation, or cardiovascular death), the components thereof, and all-cause mortality were analysed by the tertile of baseline RC (lowest, middle, and highest). We followed 8206 patients for 3.33 years (median). The adjusted hazard ratios (HRs) [95% confidence interval (CI)] for the primary outcome were 1.06 (0.73–1.56), 0.58 (0.38–0.87), and 0.67 (0.46–0.96) in the lowest, middle, and highest RC tertiles, respectively (P for interaction = 0.11). However, significant heterogeneity in the treatment effects was observed when comparing the upper two tertiles with the lowest tertile (P for interaction = 0.033). For all-cause mortality, the adjusted HRs (95% CI) were 2.48 (1.30–4.73), 1.37 (0.71–2.65), and 0.42 (0.22–0.80) in the lowest, middle, and highest RC tertiles, respectively (P for interaction <0.0001). Conclusion: Baseline RC concentrations were associated with the effects of intensive SBP lowering on the primary composite cardiovascular outcome and all-cause mortality in hypertensive patients. These results are hypothesis-generating and merit further study. Registration: STEP ClinicalTrials.gov number: NCT03015311
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that high levels of RC are closely related to CVDs such as ischemic heart disease (IHD) (10, 11), peripheral arterial disease (PAD) (12, 13), and hypertension (14, 15).”
From Remnant cholesterol, lipid ratios, and the severity of coronary artery lesions: a retrospective cohort study in patients with coronary heart disease (2025) · cites this paper as [14]
Citations
Cites
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension
Zhang, W., Zhang, S., Deng, Y., Wu, S., Ren, J., Sun, G., Yang, J., Jiang, Y., Xu, X., Wang, T.-D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2111437 · Cited by 784
Self-citationTriglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Jepsen, A.-M. K., Langsted, A., Varbo, A., Bang, L. E., Kamstrup, P. R., & Nordestgaard, B. G. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.253757 · Cited by 218
Research works printed but not linked: 37
- Bruemmer, 2021, Remnant cholesterol: the leftovers and their contribution to atherosclerotic cardiovascular disease, Circ Cardiovasc Imaging, 14, e012615, 10.1161/CIRCIMAGING.121.012615 · DOI
- Pirillo, 2020, Beyond LDL-C levels, does remnant cholesterol estimation matter?, Eur J Prev Cardiol, 27, 1088, 10.1177/2047487319899622 · DOI
- Jørgensen, 2013, Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction, Eur Heart J, 34, 1826, 10.1093/eurheartj/ehs431 · DOI · Paper page
- Kaltoft, 2020, Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study, Eur Heart J, 41, 2288, 10.1093/eurheartj/ehaa172 · DOI · Paper page
- Varbo, 2013, Remnant cholesterol as a causal risk factor for ischemic heart disease, J Am Coll Cardiol, 61, 427, 10.1016/j.jacc.2012.08.1026 · DOI · Paper page
- Gao, 2022, Remnant cholesterol predicts risk of cardiovascular events in patients with myocardial infarction with nonobstructive coronary arteries, J Am Heart Assoc, 11, e024366, 10.1161/JAHA.121.024366 · DOI
- Vallejo-Vaz, 2018, Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial, Circulation, 138, 770, 10.1161/CIRCULATIONAHA.117.032318 · DOI · Paper page
- Li, 2022, Remnant cholesterol variability and incident ischemic stroke in the general population, Stroke, 53, 1934, 10.1161/STROKEAHA.121.037756 · DOI
- Quispe, 2021, Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study, Eur Heart J, 42, 4324, 10.1093/eurheartj/ehab432 · DOI · Paper page
- Wang, 2022, Association between remnant cholesterol and arterial stiffness: a secondary analysis based on a cross-sectional study, J Clin Hypertens, 24, 26, 10.1111/jch.14384 · DOI
- Li, 2021, Associations between remnant lipoprotein cholesterol and central systolic blood pressure in a Chinese community-based population: a cross-sectional study, Lipids Health Dis, 20, 60, 10.1186/s12944-021-01490-0 · DOI
- Kasahara, 2013, High level of plasma remnant-like particle cholesterol may predispose to development of hypertension in normotensive subjects, Am J Hypertens, 26, 793, 10.1093/ajh/hpt011 · DOI
- Chen, 2022, High remnant cholesterol level potentiates the development of hypertension, Front Endocrinol, 13, 830347, 10.3389/fendo.2022.830347 · DOI · Paper page
- Wang, 2022, The association of remnant cholesterol (RC) and interaction between RC and diabetes on the subsequent risk of hypertension, Front Endocrinol, 13, 951635, 10.3389/fendo.2022.951635 · DOI
- Xu, 2021, Change in postprandial level of remnant cholesterol after a daily breakfast in Chinese patients with hypertension, Front Cardiovasc Med, 8, 685385, 10.3389/fcvm.2021.685385 · DOI
- Zheng, 2022, Hypertension, remnant cholesterol and cardiovascular disease: evidence from the China health and retirement longitudinal study, J Hypertens, 40, 2292, 10.1097/HJH.0000000000003259 · DOI
- Zhang, 2020, Strategy of blood pressure intervention in the elderly hypertensive patients (STEP): rational, design, and baseline characteristics for the main trial, Contemp Clin Trials, 89, 105913, 10.1016/j.cct.2019.105913 · DOI
- Ma, 2006, Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease, J Am Soc Nephrol, 17, 2937, 10.1681/ASN.2006040368 · DOI
- D’Agostino, 2008, General cardiovascular risk profile for use in primary care, Circulation, 117, 743, 10.1161/CIRCULATIONAHA.107.699579 · DOI · Paper page
- Castañer, 2020, Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease, J Am Coll Cardiol, 76, 2712, 10.1016/j.jacc.2020.10.008 · DOI · Paper page
- Elshazly, 2020, Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease, Eur J Prev Cardiol, 27, 1091, 10.1177/2047487319887578 · DOI · Paper page
- Liu, 2022, Association between remnant cholesterol and arterial stiffness in a Chinese community-based population: a cross-sectional study, Front Cardiovasc Med, 9, 993097, 10.3389/fcvm.2022.993097 · DOI
- Charakida, 2010, Assessment of atherosclerosis: the role of flow-mediated dilatation, Eur Heart J, 31, 2854, 10.1093/eurheartj/ehq340 · DOI
- Dinh, 2014, Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension, BioMed Res Int, 2014, 406960, 10.1155/2014/406960 · DOI
- Ohnishi, 2002, Relationship between insulin-resistance and remnant-like particle cholesterol, Atherosclerosis, 164, 167, 10.1016/S0021-9150(02)00057-6 · DOI
- Inoue, 2002, Possible relationship between insulin resistance and remnant-like lipoprotein particles in coronary endothelial dysfunction, Clin Cardiol, 25, 532, 10.1002/clc.4960251110 · DOI
- Huang, 2022, Emerging evidence of pathological roles of very-low-density lipoprotein (VLDL), Int J Mol Sci, 23, 4300, 10.3390/ijms23084300 · DOI
- Tsai, 2017, Very low-density lipoprotein (VLDL)-induced signals mediating aldosterone production, J Endocrinol, 232, R115, 10.1530/JOE-16-0237 · DOI
- The SPRINT Research Group, 2015, A randomized trial of intensive versus standard blood-pressure control, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939 · DOI · Paper page
- Phillips, 2018, Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension, J Am Coll Cardiol, 71, 1601, 10.1016/j.jacc.2018.01.074 · DOI · Paper page
- Bress, 2021, Patient selection for intensive blood pressure management based on benefit and adverse events, J Am Coll Cardiol, 77, 1977, 10.1016/j.jacc.2021.02.058 · DOI
- Attar, 2019, Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: a secondary analysis of the SPRINT trial, Eur J Prev Cardiol, 26, 238, 10.1177/2047487318800741 · DOI
- Cheng, 2021, The U-shaped association of non-high-density lipoprotein cholesterol levels with all-cause and cardiovascular mortality among patients with hypertension, Front Cardiovasc Med, 8, 707701, 10.3389/fcvm.2021.707701 · DOI
- Johannesen, 2020, Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study, BMJ, 371, m4266, 10.1136/bmj.m4266 · DOI
- Nordestgaard, 2018, Advances in lipid-lowering therapy through gene-silencing technologies, Nat Rev Cardiol, 15, 261, 10.1038/nrcardio.2018.3 · DOI
- Varbo, 2021, Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction, Eur Heart J, 42, 4833, 10.1093/eurheartj/ehab293 · DOI
- Wadström, 2023, Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality, Eur Heart J, 44, 1432, 10.1093/eurheartj/ehac822 · DOI
Cited by
Sorted by citations
Higher blood pressure targets for hypertension in older adults
Falk, J., Froentjes, L. S., Kirkwood, J. E. M., Heran, B. S., Kolber, M. R., Allan, G. M., Korownyk, C. S., & Garrison, S. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011575.pub3 · Cited by 13
Li, Y., Zhai, Y., Hu, S., Liu, J., Zhang, W., Yue, J., & Wang, Z. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1516326 · Cited by 7
Zhang, P., Liu, Y.-H., Xiong, W.-Y., Fan, Y.-B., Zhu, X., Zhou, K., & Li, H. (2025) · HORMONES · doi:10.1007/s42000-025-00651-5 · Cited by 2
Li, H., He, Q., Wenqing, Z., Yanjun, Z., Wangjia, P., Shikai, Y., Zhuoga, D., Zhang, Y., & Zhao, Y. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15232 · Cited by 3
Li, Y., Chen, Z.-Y., Shang, L., Wang, Y.-H., Liu, X.-Y., Yang, Y.-H., & He, L. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1770876
Metadata
- Authors
- Yang, R., Zhang, J., Yu, X., Yang, G., & Cai, J.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Shanxi Medical University (CN)
- Department of Cardiology, Benxi Railway Hospital , No. 25 Yingchun Street, Pingshan District, Benxi, Liaoning Province 117000 , China
- Chinese People's Armed Police Force (CN)
- Corresponding author
- Cai, Jun
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-01-03
- Volume
- 31
- Issue
- 8
- Pages
- 997-1004
- ISSN
- 2047-4873 (ISSN-L)
- 2047-4881
- OpenAlex
- W4390531708
- Cited by
- 12
- References
- 0
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 2
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Preventive Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- CAMS Innovation Fund for Medical Sciences (2021-I2M-1-007)
- National Natural Science Foundation of China (81825002)
- Beijing Outstanding Young Scientist Program (BJJWZYJH01201910023029)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- remnant cholesterol, intensive blood pressure lowering, systolic blood pressure, hypertension, older adults, cardiovascular outcomes, all-cause mortality, treatment effect heterogeneity, STEP trial
- MeSH terms
- Age Factors, Aged, Aged, 80 and over, Antihypertensive Agents, Blood Pressure, Cholesterol, Female, Humans, Hypertension, Male, Risk Factors, Time Factors, Biomarkers, Treatment Outcome, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review